Peptides & Complex Generics Symposium 2026

Be a part of India's largest Peptides and Complex Generics Symposium 2026

ATTENDEES

SPEAKERS

PARTNERS

SCIENTIFIC POSTERS

WORKSHOPS

Building dialogue

What's next in the GLP-1 Race?

How to scale peptides from lab to market?

Is India ready to lead in complex therapeutics?

Are oligonucleotides the future?

Can India power the next Billion-Dose era?

ABOUT PCG 2026

The Peptides & Complex Generics Symposium (PCG 2026), organized by Mumbai Biocluster and ICT Mumbai, brings together a curated community of industry leaders, researchers, regulators, CDMOs, startups, and investors to address the evolving landscape of next-generation therapeutics.

As a high-impact platform, it features focused discussions across peptides, complex generics, oligonucleotides and advanced therapeutics.

WHAT'S NEW?

PCG 2026 expands its lens to Oligonucleotide therapeutics, with a stronger focus on GLP-1, advanced delivery systems, and AI-driven drug development.

WHY ATTEND?

Be a part of transformative conversations like never before. Connect with key stakeholders, uncover opportunities in emerging therapeutics, and gain insights to translate innovation into real-world solutions.

Abstract Submission Deadline

August 7th, 2026

Last Date of Registration

September 20th, 2026

Date of
Event

September 28-29, 2026

BILLION DOSE CHALLENGE

As the industry shifts from breakthrough science to mass production, PCG 2026 addresses how the Indian ecosystem can accelerate to meet global GLP-1 demand and expanding CDMO ambitions while strictly ensuring GMP compliance, operational excellence, and global trust.

PROGRAM HIGHLIGHTS

Driving into technical complexities shaping the global therapeutics landscape.

Subject to Modifications

Plenary Panels

Billion Dose Challenge: Can India Scale Without Compromising Quality
Beyond China+1: Building a Resilient Global Supply Chain for Complex Therapeutics
Next Blockbuster for Metabolic Disorders
Scaling Oligonucleotide Manufacturing: From Process to Production

Scientific Sessions

Immunogenicity Risk in Peptides & Oligonucleotides: From Prediction to Clinical Impact
Next-Gen Materials in Drug Delivery: Enabling Bioavailability, Stability & Cost Efficiency
Regulatory Pathways for Complex Therapeutics: From Sameness to Speed
From Synthesis to Scale-Up: Manufacturing Challenges and Process Optimization
Analytical Characterization: Addressing Structural Complexity and Comparability

Spotlight Sessions

Device & Packaging: Shift to Smart Autoinjector and track & trace technology
AI Advantage: Turning ML into Faster, Smarter Drug Development

PCG 2025 MOMENTS

Where it all Began

Industry leaders Mr. Namit Joshi, Mr. Sudarshan Jain, Mr. Ajit Singh, and Dr. Ratnesh Jain marked the inauguration of PCG 2025.

GLP-1 Plenary Panel: Moderated by Vikas Dandekar (The Economic Times), with Vikrant Shrotriya (Novo Nordisk), Siddharth Mittal (Biocon Ltd.), Winselow Tucker (Eli Lilly India), Dr. Subramanian Narayanaswamy (Dr. Reddy's Laboratories), and Jatin Vimal (Levim Lifetech Pvt. Ltd.).

Plenary Panel: Reimagining India's Pharma Leadership. Moderated by Dr. Ratnesh Jain (Mumbai Biocluster), with Ajit Singh (IPEC India), Bhushan Akshikar (OPPI), Namit Joshi (Pharmexcil), Mehul M. Shah (IDMA), and Dr. Rajiv Desai (IPA).

Market Expo Highlights: A dynamic exhibition space where companies presented cutting-edge solutions and connected with industry stakeholders.

Poster Presentations: Brought together academic and industry research through interactive scientific exchange.

PEPTIDES & COMPLEX
GENERICS SYMPOSIUM

Be a part of India's largest Peptides and Complex Generics Symposium 2026

KEY HIGHLIGHTS

Scientific Sessions

Poster Presentations

Molecule To Market Expo

Workshops